Summit Therapeutics (SMMT) Sheds 10.4%, This Analyst is Pessimistic
In a market note during the day, Bernstein reaffirmed its underperform rating for Summit Therapeutics Inc.
America Forever Bytes
Other
In a market note during the day, Bernstein reaffirmed its underperform rating for Summit Therapeutics Inc.